Impact of Thoracic Duct Ligation on Postoperative Weight Reduction in Obese Patients Receiving Minimally Invasive Lung Surgery: A Clinical Investigation

ConditionObese Patients

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-75

SponsorYongxin Zhou

About this trial

This clinical trial aims to investigate whether thoracic duct ligation (TDL) can improve obesity and lipid metabolism. The primary questions it seeks to answer are:

Whether thoracic duct ligation can improve BMI and lipid metabolism in obese patients.

The safety and feasibility of thoracic duct ligation as a treatment for obesity.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age & Gender: Individuals aged 18-75 years, regardless of gender.

Clinical Profile:Diagnosed with early-stage lung cancer (stage IA1-IB) and obesity (BMI ≥28 kg/m²).

Scheduled to undergo video-assisted thoracoscopic surgery (VATS) for right-sided lung cancer resection at our institution between October 2024 and October 2026.

Surgical Eligibility: Approved for surgery following multidisciplinary team (MDT) assessment.

Disqualifiers

Concurrent Thoracic Infections: Patients with active intrathoracic infectious diseases (e.g., inflammatory conditions, tuberculosis).

Refusal of Novel Technique: Patients unwilling to undergo intraoperative thoracic duct ligation.

Clinically Unstable Comorbidities: Severe, unstable cardiovascular, renal, or respiratory disorders.

Prior Bariatric Surgery: History of weight-loss surgery (e.g., gastric bypass, sleeve gastrectomy).

Trial design

Design model

Single group

Treatments tested in this trial

Thoracic Duct Ligation (TDL)
Procedure/Surgery
Following the minimally invasive right-sided lung cancer resection, during mediastinal lymph node dissection, the posterior aspect of the azygos vein is identified. The mediastinal pleura is then longitudinally incised along the medial border of the azygos vein and posterior to the esophagus. Between the azygos vein and aorta, the thoracic duct is meticulously localized as a milky-white translucent structure measuring 2-3 mm in diameter. A 5-mm segment of the duct is carefully mobilized and double-clamped with vascular clips under direct thoracoscopic visualization. The surgical field is thoroughly inspected to confirm the absence of chylous leakage, and the procedure is concluded after standard closure and confirmation of hemostasis.

Treatment groups

16 Participants

are divided into 1 treatment group

Group A: Thoracic Duct Ligation (TDL)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

Height and weight (for BMI calculation)

Time frame

Height and weight (for BMI calculation) : Measured at baseline, postoperative 1/4/ 7/10/13/19/25/37months.;Lipid profile (LDL/HDL): Baseline, postoperative 1/5day, 1/4/ 7/10/13/19/25/37months.Participants will be followed for up to 36 months .

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Yongxin Zhou

Lead sponsor

Shanghai Tongji Hospital, Tongji University School of Medicine

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: